Suppr超能文献

诱导淋巴细胞减少后阻断髓系来源的抑制细胞可改善黑色素瘤小鼠模型中的过继 T 细胞治疗。

Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.

机构信息

Immunology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

出版信息

J Immunol. 2012 Dec 1;189(11):5147-54. doi: 10.4049/jimmunol.1200274. Epub 2012 Oct 24.

Abstract

Administration of nonmyeloablative chemotherapeutic agents or total body irradiation (TBI) prior to adoptive transfer of tumor-specific T cells may reduce or eliminate immunosuppressive populations such as T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSC). Little is known about these populations during immune reconstitution. This study was designed to understand the reconstitution rate and function of these populations post TBI in melanoma tumor-bearing mice. Reconstitution rate and suppressive activity of CD4(+)CD25(+)Foxp3(+) Tregs and CD11b(+)Gr1(+) MDSC following TBI-induced lymphopenia was measured in B16 melanoma tumor-bearing mice. To ablate the rapid reconstitution of suppressive populations, we treated mice with docetaxel, a known chemotherapeutic agent that targets MDSC, in combination with adoptive T cell transfer and dendritic cell immunotherapy. Both Treg and MDSC populations exhibited rapid reconstitution after TBI-induced lymphopenia. Although reconstituted Tregs were just as suppressive as Tregs from untreated mice, MDSC demonstrated enhanced suppressive activity of CD8(+) T cell proliferation compared with endogenous MDSC from tumor-bearing mice. TBI-induced lymphopenia followed by docetaxel treatment improved the efficacy of adoptive T cell transfer and dendritic cell immunotherapy in melanoma-bearing mice, inducing a significant reduction in tumor growth and enhancing survival. Tumor regression correlated with increased CTL activity and persistence of adoptively transferred T cells. Overall, these findings suggest that TBI-induced MDSC are highly immunosuppressive and blocking their rapid reconstitution may improve the efficacy of vaccination strategies and adoptive immunotherapy.

摘要

在过继输注肿瘤特异性 T 细胞之前,给予非清髓性化疗药物或全身照射(TBI)可能会减少或消除免疫抑制群体,如调节性 T 细胞(Tregs)和髓源抑制细胞(MDSC)。关于这些群体在免疫重建期间的情况知之甚少。本研究旨在了解 TBI 后在黑色素瘤荷瘤小鼠中这些群体的重建率和功能。在 B16 黑色素瘤荷瘤小鼠中,测量 TBI 诱导的淋巴细胞减少后 CD4(+)CD25(+)Foxp3(+)Tregs 和 CD11b(+)Gr1(+)MDSC 的重建率和抑制活性。为了消除抑制性群体的快速重建,我们用多西紫杉醇(一种针对 MDSC 的已知化疗药物)联合过继性 T 细胞转移和树突状细胞免疫疗法治疗小鼠。TBI 诱导的淋巴细胞减少后,Treg 和 MDSC 群体均迅速重建。尽管重建的 Tregs 与未处理小鼠的 Tregs 一样具有抑制作用,但与荷瘤小鼠内源性 MDSC 相比,MDSC 对 CD8(+)T 细胞增殖的抑制活性增强。TBI 诱导的淋巴细胞减少后用多西紫杉醇治疗可提高黑色素瘤荷瘤小鼠过继性 T 细胞转移和树突状细胞免疫疗法的疗效,显著减少肿瘤生长并提高存活率。肿瘤消退与 CTL 活性的增加和过继转移 T 细胞的持续存在相关。总的来说,这些发现表明 TBI 诱导的 MDSC 具有高度的免疫抑制作用,阻断其快速重建可能会提高疫苗策略和过继免疫疗法的疗效。

相似文献

3
CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice.
Eur J Immunol. 2010 May;40(5):1375-85. doi: 10.1002/eji.200839210.
8
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.
Clin Cancer Res. 2008 May 15;14(10):3156-67. doi: 10.1158/1078-0432.CCR-07-4696.

引用本文的文献

1
Immunotherapy Resistance and Therapeutic Strategies in PD-L1 High Expression Non-Small Cell Lung Cancer.
Onco Targets Ther. 2025 Aug 29;18:953-966. doi: 10.2147/OTT.S539978. eCollection 2025.
2
Knockout cancer by nano-delivered immunotherapy using perfusion-aided scaffold-based tumor-on-a-chip.
Nanotheranostics. 2024 Mar 31;8(3):380-400. doi: 10.7150/ntno.87818. eCollection 2024.
3
Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine?
Front Immunol. 2023 Nov 22;14:1329850. doi: 10.3389/fimmu.2023.1329850. eCollection 2023.
4
It's high-time to re-evaluate the value of induced-chemotherapy for reinforcing immunotherapy in colorectal cancer.
Front Immunol. 2023 Oct 18;14:1241208. doi: 10.3389/fimmu.2023.1241208. eCollection 2023.
5
A new approach to overcoming resistance to immunotherapy: nanotechnology.
Front Oncol. 2023 Aug 10;13:1210245. doi: 10.3389/fonc.2023.1210245. eCollection 2023.
6
Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling.
Cancer Res Commun. 2023 Mar 9;3(3):404-419. doi: 10.1158/2767-9764.CRC-22-0278. eCollection 2023 Mar.
7
Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies.
Int J Mol Sci. 2022 Sep 18;23(18):10906. doi: 10.3390/ijms231810906.
8
Adoptive cell therapies in thoracic malignancies.
Cancer Immunol Immunother. 2022 Sep;71(9):2077-2098. doi: 10.1007/s00262-022-03142-3. Epub 2022 Feb 7.
9
The current landscape of immunotherapy for pediatric brain tumors.
Nat Cancer. 2022 Jan;3(1):11-24. doi: 10.1038/s43018-021-00319-0. Epub 2022 Jan 20.
10
Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4 Th1 Responses and Potential Use as a Cancer Vaccine.
Cancer Immunol Res. 2022 Jan;10(1):108-125. doi: 10.1158/2326-6066.CIR-21-0454. Epub 2021 Nov 16.

本文引用的文献

1
Coordinated regulation of myeloid cells by tumours.
Nat Rev Immunol. 2012 Mar 22;12(4):253-68. doi: 10.1038/nri3175.
2
The secret ally: immunostimulation by anticancer drugs.
Nat Rev Drug Discov. 2012 Feb 3;11(3):215-33. doi: 10.1038/nrd3626.
3
Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner.
J Immunotoxicol. 2012 Jul-Sep;9(3):292-300. doi: 10.3109/1547691X.2011.642418. Epub 2012 Jan 28.
4
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
Blood. 2011 Sep 15;118(11):3003-12. doi: 10.1182/blood-2011-02-334565. Epub 2011 Jul 18.
5
Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.
Clin Cancer Res. 2010 Oct 15;16(20):5067-78. doi: 10.1158/1078-0432.CCR-10-1757. Epub 2010 Aug 24.
6
A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.
Clin Cancer Res. 2010 Sep 15;16(18):4583-94. doi: 10.1158/1078-0432.CCR-10-0733. Epub 2010 Aug 11.
7
Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.
Cancer Res. 2010 Jun 1;70(11):4335-45. doi: 10.1158/0008-5472.CAN-09-3767. Epub 2010 May 18.
8
Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer.
Clin Cancer Res. 2010 Mar 15;16(6):1812-23. doi: 10.1158/1078-0432.CCR-09-3272. Epub 2010 Mar 9.
9
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
J Immunol. 2010 Apr 1;184(7):3442-9. doi: 10.4049/jimmunol.0904114. Epub 2010 Mar 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验